Gentian Diagnostics ASA
OSE:GENT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (37.6), the stock would be worth kr89.12 (105% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 18.4 | kr43.5 |
0%
|
| 3-Year Average | 37.6 | kr89.12 |
+105%
|
| Industry Average | 22.1 | kr52.25 |
+20%
|
| Country Average | 14.3 | kr33.83 |
-22%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| NO |
G
|
Gentian Diagnostics ASA
OSE:GENT
|
670.9m NOK | 18.4 | 50.6 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.9T JPY | 47.5 | 39.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
29B CHF | 24 | 36.4 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
92B DKK | 20.7 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 23.7 | 31 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 24.2 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38B CNY | 31.8 | 23 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
905.8B JPY | 25.5 | 51.2 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -75.9 | -37.9 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.4B USD | -152.6 | -15 |
Market Distribution
| Min | 0 |
| 30th Percentile | 3.1 |
| Median | 14.3 |
| 70th Percentile | 24 |
| Max | 131 605.6 |
Other Multiples
Gentian Diagnostics ASA
Glance View
Gentian Diagnostics ASA is a medical diagnostics company. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
